# OnCo record paper-ielsg32-matrix-induction-ferreri-lancet-haematol-2016 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-ielsg32-matrix-induction-ferreri-lancet-haematol-2016/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-ielsg32-matrix-induction-ferreri-lancet-haematol-2016" ;
  schema:name "IELSG32 first randomisation: the MATRix regimen (methotrexate, cytarabine, thiotepa, rituximab) in primary CNS lymphoma"@en ;
  schema:description "Adding rituximab and thiotepa to methotrexate and cytarabine doubled the complete remission rate for lymphoma confined to the brain, making the four-drug MATRix regimen the standard induction for patients up to 70."@en ;
  schema:url <https://onco.cc/key-papers/paper-ielsg32-matrix-induction-ferreri-lancet-haematol-2016/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S2352-3026(16)00036-3>, <https://pubmed.ncbi.nlm.nih.gov/27132696/> ;
  schema:sameAs <https://doi.org/10.1016/S2352-3026(16)00036-3> ;
  schema:datePublished "2016"^^xsd:gYear ;
  schema:author "Ferreri AJ, Cwynarski K, Pulczynski E, et al." ;
  onco:cancers <https://onco.cc/cancers/primary-cns-lymphoma/> ;
  onco:drugs <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/drugs/cytarabine/>, <https://onco.cc/drugs/thiotepa/>, <https://onco.cc/drugs/rituximab/> ;
  onco:trials <https://onco.cc/trials/ielsg32/> ;
  onco:journals <https://onco.cc/journals/lancet-haematology/> .